BerGenBio

Share Issue/Capital Change • May 4, 2020

BERGENBIO ASA - PRIVATE PLACEMENT SUCCESSFULLY PLACED

BERGENBIO ASA - PRIVATE PLACEMENT SUCCESSFULLY PLACED

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE

SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG

SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA OR

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE

UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT

THE END OF THE PRESS RELEASE

Bergen, 4 May 2020: Reference is made to the stock exchange announcement by

BerGenBio ASA (OSE:BGBIO) ("BerGenBio" or the "Company") on 4 May 2020 regarding

a contemplated private placement of new shares in the Company (the "Private

Placement").

The Company is pleased to announce that the Private Placement has been

successfully placed, raising gross proceeds of NOK 500 million through the

allocation of 13,325,000 shares at a subscription price of NOK 37.50 per share

(the "Subscription Price"). The Private Placement, that was oversubscribed, took

place through an accelerated book building process after close of market on 4

May 2020. Arctic Securities AS, Carnegie AS and DNB Markets, a part of DNB Bank

ASA acted as Joint Bookrunners (together the "Managers") in connection with the

Private Placement.

The Company intends to use the net proceeds from the Private Placement to take

full advantage of clinical development opportunities stemming from the Company's

technology and to progress readiness for early commercialisation possibilities,

as well as for general corporate purposes.

In connection with the Private Placement, a group of employees in the Company

realized a small portion of their existing shares or shares acquired through

exercise of options, in total 302,500 shares in the Company, at the same price

as the subscription price in the Private Placement (the "Secondary Sale", and

together with the Private Placement the "Transaction"). The following primary

insiders either subscribed for shares or sold shares or options in the

Transaction:

Meteva AS, represented on the board of directors by Sveinung Hole, was allocated

1,706,667 shares in the Transaction. Following the Transaction, Meteva will own

21,956,142 shares in the Company, equal to 25.32% of the share capital.

Altitude Capital AS, represented on the board of directors by Grunde Eriksen,

was allocated 65,000 shares in the Transaction. Following the Transaction,

Altitude Capital AS, will own 780,000 shares in the Company, equal to 0.90% of

the share capital.

Richard Godfrey (Chief Executive Officer and primary insider) has through Gnist

Holding AS sold 200,000 existing shares in the Company as part of the

Transaction. Following the Transaction, Richard Godfrey will own 21,005 shares

(equal to 0.02% of the share capital) and 1,542,617 options in the Company.

Endre Kjærland (Associate Director of IP and Contracts and primary insider) will

as part of the Transaction exercise options and sell 20,000 shares. Following

the Transaction, Endre Kjærland will own 3,262 shares (equal to 0.004% of the

share capital) and 130,525 options in the Company.

Gro Gausdal (Director of Research & Bergen Site Leader and primary insider) will

as part of the Transaction exercise options and sell 15,000 shares. Following

the Transaction, Gro Gausdal will own 143,376 options in the Company.

In addition, non-primary insiders among the Company's employees will exercise

options and sell 67,500 shares as part of the Transaction. The selling employees

will enter into a customary 6 months lock-up undertaking on their remaining

holdings with the Joint Bookrunners.

The shares allocated in the Transaction will be settled through a delivery

versus payment transaction on a regular T+2 basis by delivery of existing and

unencumbered shares in the Company that are already listed on the Oslo Stock

Exchange pursuant to a share lending agreement between Arctic Securities (on

behalf of the Managers), the Company, the sellers in the Secondary Sale and

Meteva AS. The shares delivered to the applicants will thus be tradable from

allocation. The Managers will settle the share loan with new shares in the

Company to be issued by the board of directors of the Company (the "Board")

pursuant to an authorization granted at the Company's annual general meeting

held on 16 March 2020. Notification of allocation of shares and payment

instructions is expected to be sent to the applicants through a notification

from the Managers on 5 May 2020.

Following registration of the new share capital in the Company and issuance of

the new shares in the Transaction (including options exercised by employees)

with the Norwegian Register of Business Enterprises, which is expected to take

place on or about 7 May 2020, the Company will have an issued share capital of

NOK 8,672,580.50 divided into 86,725,805 shares, each with a par value of NOK

0.10.

Completion of the Private Placement implies a deviation from the existing

shareholders' pre-emptive rights to subscribe for and be allocated new shares.

The Board has considered the Private Placement in light of the equal treatment

obligations under under the Norwegian Securities Trading Act and Oslo Børs'

Circular no. 2/2014, and is of the opinion that the proposed Private Placement

is in compliance with these requirements. Following careful considerations, the

Board is of the view that it will be in the common interest of the Company and

its shareholders to raise equity through a Private Placement setting aside the

pre-emptive rights of the existing shareholders to subscribe for shares. By

structuring the transaction as a Private Placement, the Company will be in a

position to raise capital in an efficient manner, with a lower discount to the

current trading price and with significantly lower completion risks compared to

a rights issue. In addition, the Private Placement was marketed through a

publicly announced bookbuilding process.

Subject to inter alia (i) completion of the Private Placement, (ii) relevant

corporate resolutions including approval by the Board and the EGM, (iii)

prevailing market price of the Company's shares being noticeably higher than the

subscription price, and (iv) approval by the Financial Supervisory Authority of

Norway of a prospectus (the "Prospectus"), the Company will carry out a

subsequent offering (the "Subsequent Offering") of up to 1,500,000 new shares in

the Company. A Subsequent Offering will, if made, and on the basis of the

Prospectus, be directed towards eligible shareholders in the Company who (i) are

shareholders in the Company as of 4 May 2020, as registered as shareholders in

the Company's register of shareholders with the Norwegian Central Securities

Depositary (Nw. Verdipapirsentralen) (the "VPS") as of 6 May 2020, (ii) are not

allocated shares in the Private Placement, (iii) are not resident in a

jurisdiction where such offering would be unlawful or, for jurisdictions other

than Norway, would require any prospectus, filing, registration or similar

action, and (iv) have an existing shareholding below a threshold of 150,000

shares in the Company (the "Eligible Shareholders"). The Eligible Shareholders

are expected to be granted non-tradable allocation rights. The subscription

period in the Subsequent Offering is expected to commence shortly after

publication of the Prospectus, and the subscription price in the Subsequent

Offering will be the same as in the Private Placement. When deciding the need

for and size of a potential subsequent offering, the Board will factor in the

amount of upcoming short-term news flow in connection with the Company's

participation in the ACCORD study related to Covid-19 (including the need to

avoid that a subsequent offering will provide the Eligible Shareholders with an

unreasonable option value). The Board will also consider the trading volume and

market price of the shares in the Company in the intermediate period. The

Company will issue a separate stock exchange notice with further details on the

Subsequent Offering if and when finally resolved.

Advokatfirmaet Thommessen AS acts as legal advisor to the Company in connection

with the Private Placement.

For further information, please contact:

Richard Godfrey, CEO

richard.godfrey@bergenbio.com

+47 917 86 304

Rune Skeie, CFO

rune.skeie@bergenbio.com

+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II oncology clinical development

programme focused on combination and single agent therapy in lung cancer and

leukaemia. A first-in-class functional blocking AXL antibody, tilvestamab

(BGB149) is undergoing phase I clinical testing. In parallel, BerGenBio is

developing a companion diagnostic test to identify those patient populations

most likely to benefit from bemcentinib: this is expected to facilitate more

efficient registration trials supporting a precision medicine-based

commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com

***

- IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or

subscribe for shares. Copies of this document may not be sent to jurisdictions,

or distributed in or sent from jurisdictions, in which this is barred or

prohibited by law. The information contained herein shall not constitute an

offer to sell or the solicitation of an offer to buy, in any jurisdiction in

which such offer or solicitation would be unlawful prior to registration,

exemption from registration or qualification under the securities laws of any

jurisdiction.

This communication may not be published, distributed or transmitted in or into

the United States, Canada, Australia, the Hong Kong Special Administrative

Region of the People's Republic of China, South Africa or Japan and it does not

constitute an offer or invitation to subscribe for or purchase any securities in

such countries or in any other jurisdiction. In particular, the document and the

information contained herein should not be distributed or otherwise transmitted

into the United States of America or to U.S. persons (as defined in the U.S.

Securities Act of 1933, as amended (the "Securities Act")) or to publications

with a general circulation in the United States of America. This document is not

an offer for sale of securities in the United States. The securities referred to

herein have not been and will not be registered under the Securities Act, or the

laws of any state, and may not be offered or sold in the United States of

America absent registration under or an exemption from registration under

Securities Act. BerGenBio does not intend to register any part of the offering

in the United States. There will be no public offering of the securities in the

United States of America.

The information contained herein does not constitute an offer of securities to

the public in the United Kingdom. No prospectus offering securities to the

public will be published in the United Kingdom. This document is only being

distributed to and is only directed at (i) persons who are outside the United

Kingdom or (ii) to investment professionals falling within article 19(5) of the

Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the

"Order") or (iii) high net worth entities, and other persons to whom it may

lawfully be communicated, falling within article 49(2)(a) to (d) of the Order

(all such persons together being referred to as "relevant persons"). The

securities are only available to, and any invitation, offer or agreement to

subscribe, purchase or otherwise acquire such securities will be engaged in only

with, relevant persons. Any person who is not a relevant person should not act

or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to

this communication in any member state of the European Economic Area (each an

"EEA Member State") that has implemented Directive 2003/71/EC (together with the

2010 PD Amending Directive 2010/73/EU, including any applicable implementing

measures in any Member State, the "Prospectus Directive") is only addressed to

qualified investors in that Member State within the meaning of the Prospectus

Directive. This announcement is not a prospectus within the meaning of the

Prospectus Directive, as implemented in each member State of the European

Economic Area. With respect to the EEA Member States, no action has been

undertaken or will be undertaken to make an offer to the public of the

securities referred to herein requiring a publication of a prospectus in any

Member State. As a result, the securities of the Company may not and will not be

offered in any Member State except in accordance with the exemptions set forth

in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.

statements including terms like "believe", "assume", "expect", "forecast",

"project", "may", "could", "might", "will" or similar expressions. Such forward

-looking statements are subject to known and unknown risks, uncertainties and

other factors which may result in a substantial divergence between the actual

results, financial situation, development or performance of BerGenBio and those

explicitly or implicitly presumed in these statements. Against the background of

these uncertainties, readers should not rely on forward-looking statements.

BerGenBio assumes no responsibility to update forward -looking statements or to

adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.